Quantcast

Latest Mesalazine Stories

2009-06-04 08:12:45

An electronic diagnostic tool called the SmartPill is swallowed by patients in order to take measurements as it travels through the gastrointestinal tract. A new study by physician-scientists at NewYork-Presbyterian/Weill Cornell Medical Center used the device in patients with mild to moderate ulcerative colitis (UC), determining that they have significantly more acidic pH in their colons, compared with the average person "” a finding that may impact treatment strategy.The study was...

2009-06-01 07:00:00

CHICAGO, June 1 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, presented the results of a 5-aminosalicylic acid (5-ASA) persistency analysis entitled, "Twelve-month Persistence with 5-aminosalicylic Acid Therapy: Results from a Large Pharmacy Database," at Digestive Disease Week, on May 31, 2009. Results showed that after 12 months of therapy for continuing patients, 20 percent of Lialda patients were continually persistent, 9...

2009-05-18 09:00:00

MARIETTA, Ga., May 18 /PRNewswire/ -- Ulcerative colitis (UC) is a chronic, inflammatory bowel disease (IBD) affecting half a million people in the United States, yet many patients don't always understand how to recognize or treat the symptoms associated with the disease. Ulcerative colitis is an inflammation of the lining of the rectum and colon. The disease is marked by unpredictable "flares" when the inflammation causing the disease state spikes, causing stomach pain and bloody diarrhea....

2009-05-18 08:00:00

Free Medication Provided by Shire to Patients Taking Lialda(R) (mesalamine) or Pentasa(R) (mesalamine) for the Treatment of Ulcerative Colitis Who Have Lost Their Jobs in 2009 PHILADELPHIA, May 18 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, is responding to the needs of patients who are diagnosed with ulcerative colitis (UC) and prescribed gastrointestinal (GI) medications from Shire by expanding its Patient Assistant Program...

2009-03-25 07:00:00

Today's Local Winners Eligible for Consideration in National "Proud to Be GI" Award CINCINNATI, March 25 /PRNewswire/ -- Today, the Society of Gastroenterology Nurses and Associates (SGNA), the premier society representing nursing professionals in gastroenterology and endoscopy, and Procter and Gamble Pharmaceuticals (P&GP), makers of the ulcerative colitis (UC) treatment Asacol(R) (mesalamine) delayed-release tablets, are proud to support "GI Nurses & Associates Day," a day marked...

2009-01-19 11:17:54

Researchers from the Department of Biochemistry and Molecular Biology at the Univesidad de Alcalá (UAH), confirm that N-acetyl-L-cysteine (NAC) combined with mesalamine produces a significant improvement in patients suffering from ulcerative colitis. The team headed by Luis González Guijarro, biochemistry and molecular biology professor at the UAH, in collaboration with the pharmaceutical firm Farmasierra S.L., has developed a pilot study of the effects of N-acetyl-L-cysteine on...

2008-11-05 18:00:23

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced financial and operating results for the third quarter ended September 30, 2008. Total product revenue was $42.9 million for the third quarter of 2008, compared to $67.4 million for the third quarter of 2007. Total product revenue for the first nine months of 2008 was $118.2 million compared to $193.8 million for the first nine months of 2007. The decrease in total product revenue for the quarter and nine months was due to the...

2008-11-03 12:00:26

Salix Pharmaceuticals, a specialty pharmaceutical company, has announced that the FDA has granted marketing approval for Apriso extended-release capsules 0.375gm. The approval is based on results from two randomized, double-blind, placebo-controlled multi-center, multi-national studies totaling 562 adults in remission from ulcerative colitis (UC). Apriso is a locally-acting aminosalicylate indicated for the maintenance of remission of UC adults. Additionally, Apriso is said to be the...

2008-10-31 18:00:13

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for APRISO(TM) (mesalamine) extended-release capsules 0.375 g. APRISO is a locally-acting aminosalicylate indicated for the maintenance of remission of ulcerative colitis (UC) in adults. APRISO is the first and only mesalamine product approved by the FDA for once-a-day dosing for the maintenance of remission of ulcerative colitis. Additionally, APRISO is...

2008-10-09 09:00:10

More Patients Switched to Mesalamine Granules Maintained Remission Versus Placebo (78 percent versus 59 percent) Salix Pharmaceuticals, Ltd. Adam C. Derbyshire Senior Vice President and Chief Financial Officer or G. Michael Freeman Associate Vice President, Investor Relations and Corporate Communications or Bill Forbes Pharm D. and Chief Development Officer 919-862-1000 or Media Contact: Alyssa Bleiberg, 212-485-6806 Logo: http://www.salix.com Salix...


Word of the Day
barratry
  • The offense of persistently instigating lawsuits, typically groundless ones.
  • An unlawful breach of duty on the part of a ship's master or crew resulting in injury to the ship's owner.
  • Sale or purchase of positions in church or state.
This word ultimately comes from the Old French word 'barater,' to cheat.
Related